“Either we will build a competitive industry in Europe or we will decide that it is of little importance to us and we will rely on supply chains in other parts of the world. I and the government are in favor of this proposal and a strong alliance,” he said. Adonis Georgiadis, in a panel for the pharmaceutical industry within the 7th Delphi Economic Forum, held in Delphi.
The discussion was also attended by Michele Uda, President of Egualia, Adrian Van den Hoven, General Manager of the Organization “Medicines for Europe”, Nikos Dedes, President of the Hellenic Patients Association and Dimitris Demos, Vice President of the Panhellenic Association of Pharmaceutical Industry. According to a statement, the minister praised the Greek pharmaceutical industry, saying he was proud of it, which he said “managed to overcome the crisis. Which means we have a resilient industry.” At the same time, he noted that there are structural problems in the EU regarding the drug supply chain: “I love the EU but there are pros and cons. Everything happens very slowly. They do not want many changes in decisions, but the coronavirus was a big shock. “It does not have medicines and masks. It was a positive shock because for the first time we had a discussion about how to fix our supply chain. It was something that was discussed.”
The minister also set the stage for the Russian invasion of Ukraine, saying that “it gave us another reason to secure the supply chain and I think we will see changes.” He added: “We have no time to lose. Either we make the big leap in innovation and investment in the pharmaceutical industry and rebuild a European pharmaceutical industry that is very competitive globally, competing with the US, China and India, or we decide to “We are poor relatives and our supply chains will depend on other parts of the world. As long as I firmly believe in the former, I will really strive for a strong alliance within the Member States for that. Well, yes, we have a challenge ahead of us.”
Mr Georgiadis added: “We are very good at absorbing European funding, as we have shown over the last three years, and I am very proud of that. budget, for the reasons we have explained before, but even within this framework we will still be able to absorb it, so I have no worries or thoughts about redistributing funding because we will absorb it all. , I want to say that as we support the start of the IPCI development process for health and the start of every next step in cooperation with the European Commission, IT for health and European industry, during the in the coming weeks we plan to publish a call for non-binding proposals and we expect the interest of the relevant parties in the fields of construction health industry. So you will be ready to come and start the IPCI process. ”
For his part, Michele Uda, president of Egualia, said: “The most important thing is to move really fast, because we live in a global challenge. China and India are investing heavily in their local drug industries, as is the United States. “We are meeting this challenge. It is a great opportunity but we must respond quickly.”
Adrian Van den Hoven, General Manager of Medicines for Europe, said the industry “has recognized the importance of investing in pharmaceuticals in Europe to ensure logistics sufficiency. Too many companies have increased investment across Europe”. . Addressing the Minister of Investment and Development, he praised his efforts but stressed: “The good news is that you are doing a very good job. The bad news is that you have to keep doing it. We have to bring the construction companies together to create security of supply. in Europe”.
The need to increase the use of generic drugs in Greece was mentioned, among others, by Nikos Dedes, president of the Hellenic Patients Association. “Patients are interested in accessibility but also in the sustainability of the health system. What does not provide value should be invested with very strict rules. We want to have innovative drugs, but why be more expensive? We need to increase the use of generic drugs in “Greece is only 30%. We need to improve this percentage.”
Dimitris Demos, vice president of the Panhellenic Association of the Pharmaceutical Industry and CEO of DEMO, expressed his confidence that the European strategy in the pharmaceutical industry will change sooner or later. “We can not have one winner for each announcement. We want competition systems with more than one winner. At some point we will face shortages again. They boasted about making masks a few years ago. When the pandemic is gone we will look for cheap masks again from China and India.”
Closing the conversation, the coordinator, president of the Panhellenic Pharmaceutical Industry Association, Theodoros Tryfon, said: “We are coming out of a pandemic crisis and now we have the consequences of the war. “investments of 1.5 billion euros from the pharmaceutical companies that will lead to the establishment of 12 production units. We do not want intervention, we want some disincentives to be removed”.
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
